SARS-CoV-2 mRNA vaccines have shown remarkable clinical efficacy, but questions
remain about the nature and kinetics of T cell priming. We performed longitudinal antigen …

A gradual decay in humoral and cellular immune responses over time upon SAR1S-CoV-2
vaccination may cause a lack of protective immunity. We conducted a longitudinal analysis …

Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we
characterize the dynamics of anti-viral immunity during long-term follow-up and after …

Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells …

The rapid development of mRNA-based vaccines against the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination …

Background SARS-CoV-2 vaccination has proven the most effective measure to control the
COVID-19 pandemic. Booster doses are being administered with limited knowledge on their …

Understanding vaccine-mediated protection against severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) is critical to overcoming the global coronavirus disease 2019 …

Abstract mRNA vaccines for SARS-CoV-2 have shown exceptional clinical efficacy,
providing robust protection against severe disease. However, our understanding of …

The use of coronavirus disease 2019 (COVID-19) vaccines will play the major role in
helping to end the pandemic that has killed millions worldwide. COVID-19 vaccines have …

Unlike mRNA vaccines based only on the spike protein, inactivated severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) vaccines should induce a diversified T cell …